NRAS in MDS — typically signals progression risk to AML. No targeted therapy in MDS-LR; H...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-NRAS-Q61R-MDS-LR |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-MDS-LR |
| Sources | SRC-CIVIC SRC-ESMO-MDS-2021 |
Actionability Facts
| Biomarker | BIO-RAS-MUTATION |
|---|---|
| Variant | NRAS Q61R |
| Disease | DIS-MDS-LR |
| ESCAT tier | IIIB |
| Evidence summary | NRAS in MDS — typically signals progression risk to AML. No targeted therapy in MDS-LR; HMA still standard. |
Notes
ESCAT IIIB. Under BIO-RAS-MUTATION (no dedicated BIO-NRAS-Q61R yet — flag for BIO authoring).
Used By
No reverse references found in the YAML corpus.